Results 131 to 140 of about 7,368,901 (300)

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim   +17 more
wiley   +1 more source

Osteogenic Potential of Human Mesenchymal Stem Cells and Human Embryonic Stem Cell-derived Mesodermal Progenitors : a Tissue Engineering Perspective

open access: yes, 2010
Tissue Engineering A, 16(11):3413-3426 ...
Maria de Peppo, Giuseppe   +6 more
core  

Biofabrication Strategies for Tissue Engineering

open access: yes, 2011
The success of Tissue Engineering (TE) strongly relies on the capability of designing biomimetic scaffolds closely resembling the host tissue environment.
Cometa, Stefania   +10 more
core   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

open access: yesMolecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba   +5 more
wiley   +1 more source

Nanotechnology applications for tissue engineering /

open access: yes
Tissue engineering involves seeding of cells on bio-mimicked scaffolds providing adhesive surfaces. Researchers though face a range of problems in generating tissue which can be circumvented by employing nanotechnology.
Thomas, Sabu,editor.   +2 more
core  

Tissue engineering: part 1 [Frontiers of biomedical engineering]

open access: yes, 2016
Presents a course about the basic concepts of biomedical engineering with the Professor of Chemical and Biomedical Engineering at Yale University, W. Mark Saltzman.
Saltzman, W. Mark
core   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

open access: yesMolecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir   +9 more
wiley   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

open access: yesMolecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

Tissue Engineering of Tendons [PDF]

open access: yes, 2008
Pioletti, Dominique P.   +2 more
openaire   +4 more sources

Home - About - Disclaimer - Privacy